You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Cadila Healthcare gets USFDA nod to market Decitabine Injection

Capital Market 

Cadila Healthcare has received the final approval from the US-based drug regulatory body, United States Drug & Food Administration (USFDA) to market Decitabine Injection in the strength of 50 mg/ vial Single-Dose Vial (USRLD: Dacogen).

Decitabine is used to treatmyelodysplastic syndromes, certain types of blood or bone marrow cancer. The drug will be manufactured at the group's injectables manufacturing facility at Zydus Hospira. Currently, the group has 326 approvals and has filed over 400 Abbreviated New Drug Applications (ANDAs) so far, since the commencement of the filing process in FY2003-04.

The company's consolidated net profit surged 608.10% to Rs 2999.60 crore on 2.4% increase in net sales to Rs 3,687 crore in Q2 September 2021 over Q2 September 2020.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

Shares of Cadila Healthcare fell 1.97% to close at Rs 463.15 on Thursday, 18 November 2021. The domestic stock market was shut yesterday, 19 November 2021 on account of Guru Nanak Jayanti.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sat, November 20 2021. 14:30 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU